🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Invited rad onc Dr #PhuocTran w thought provoking discussion on oligometastatic #prostatecancer, pushing limits on genomic changes & digital pathology to help understand disease biology. Last day #UTChrisWood25

Advanced PCa session at UT Chris Wood meeting led by Bilal A. Siddiqui, MD. Patrick Pilie discussed PARPi now and future directions. Ana Aparicio talked about tx of AVPC. Exciting work to molecularly define subsets of metastatic PCa

Final star studded panel to discuss challenging cases in #prostatecancer — really nice discussion from Bilal A. Siddiqui, MD Ana Aparicio #MahaHussain #KevinCourtney — way to wrap up #UTChrisWood25

Congratulations!

Wonderful! Congratulations Toni Choueiri, MD

Abstracts Open for #KCRS25 Are you shaping the future of kidney cancer care? 🔬🧬 Submit your research to the 2025 Kidney Cancer Research Summit! LINK: kcrs.kidneycan.org/kcrs25-call-fo… KidneyCAN IKCC Kidney Cancer Toni Choueiri, MD Hans Hammers Rana McKay, MD, FASCO

Abstracts Open for #KCRS25 Submit your research to the 2025 Kidney Cancer Research Summit at: kcrs.kidneycan.org/kcrs25-call-fo… KidneyCAN IKCC Kidney Cancer Toni Choueiri, MD Hans Hammers Rana McKay, MD, FASCO Sumanta K. Pal, MD, FASCO ari hakimi

Beautiful Summary on the American Biomedical and Science Leadership. 🇺🇸 We should READ this and CARE !! Killing the Science Golden Goose - The American Journal of Medicine amjmed.com/article/S0002-…

Please join us in Dallas! UTSW Simmons Cancer Center OncLive SOSS

Incredibly important. Don’t undertreat bone Mets even for pain control !

Looking forward to lively exchanges and discussions. Hopefully lots of practical insights! #kidneycancer

#ASCO25 kicks off the conversation. #WorldGU25 delivers focused updates on bladder, prostate, and kidney cancers. With esteemed faculty like Drs. Matt Milowsky, Michael Harrison, Jean Hoffman-Censits, Benjamin Garmezy, Dr. Darren Feldman, and nearly 60 other multidisciplinary thought leaders, this

Will be a great meeting! Consider joining us!

💫State of Science Novel Dx/Tx RCC & UC #ASCO25 👉Dr Rana McKay, MD, FASCO presenting Targeting #HIF2α: A New Frontier in Renal Cell Cancer Therapy 🧬 HIF2 expression is prognostic! mOS (92.6 vs 68.1mo HR 0.61, 0.51-0.73) Abst4543 Yu-Wei Chen, MD, MS 💊 Belzutifan initially approved in

Targeting HIF-2α: A new era in RCC! Presented by Dr. Rana McKay. #ASCO25 #cancer #oncology @oncoalert ASCO Kate Sears Toni Choueiri, MD Emre Yekedüz Neeraj Agarwal, MD, FASCO 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 silke gillessen Petros Grivas Vivek Subbiah, MD TwoOncDocs Oncology Brothers LARVOL Dra. María Natalia Gandur Quiroga Sumanta K. Pal, MD, FASCO

I agree. TKI/HIF2 vs potent TKI like Cabo will be close… Let’s see, but it’s becoming clear that “synergy” is unlikely

Will be fun !! #WorldGU25